MicroRNA-155 in patients with Chronic Stable Angina

  • Mohamed M Elshafae Professur of Clinical and Chemical Pathology , faculty of medicine, Benha University, Egypt
  • Jehan H Sabry Asisstant professur of Clinical and Chemical Pathology , Faculty of Medicine, Benha University, Egypt
  • Mohamed A Salem Professor of Cardiology , Faculty of Medicine, Benha university, Egypt.
  • Hanan M Elshafee
Keywords: Micro RNA 155, CSA, Gensini score, atherosclerosis, reverse-transcription PCR.

Abstract

Background: Atherosclerotic cardiovascular disease is a chronic inflammatory disease and one of the major causes of death worldwide. MicroRNAs are associated with many physiological and pathological situations as inflammation and cardiovascular disease. The communication between microRNAs, inflammation, and atherosclerosis, drive attention to the possibility that inflammation-related microRNAs, miRNA-155, could have a role in atherosclerosis progression. Objectives: We aimed to determine the levels of circulating miRNA-155 in chronic stable angina patients and to study the impact of microRNA-155 on coronary artery disease severity and extent. Methods: MicroRNA was extracted and assessed from plasma of 50 subjects (20 normal controls and 30 patients with chronic stable angina) using quantitative reverse-transcription PCR (RT-PCR). Levels were compared in the two groups and correlated with Gensini score in the group with chronic stable angina (CSA). Results: Plasma levels of microRNA 155 were significantly lower in CSA patients (0.59±0.48, 1.94±0.76, in patients and control group respectively (P<0.001). The expression of miR-155 correlated negatively with Gensini scores (P<0.001), total cholesterol (P <0.001), LDL-c (P= 0.002) and triglycerides (P= 0.03). There was a significant difference in miRNA-155 levels among the quartiles of the CSA group (P < 0.001) denoting negative correlation between microRNA 155 and coronary artery disease extent. ROC curve showed that microRNA-155 sensitivity and specificity for the prediction of severity of atherosclerosis were 86.67% and 80% respectively. Conclusion: Plasma miRNA-155 is significantly lower in CSA angina patients and levels significantly decreases with the progression of atherosclerosis. DOI: 10.21276/AABS.2017.1383

Author Biographies

Mohamed M Elshafae, Professur of Clinical and Chemical Pathology , faculty of medicine, Benha University, Egypt
clinical pathology department, faculty of medicine, Benha university, Egypt
Jehan H Sabry, Asisstant professur of Clinical and Chemical Pathology , Faculty of Medicine, Benha University, Egypt
Clinical pathology department, faculty of medicine, Benha university, Egypt
Mohamed A Salem, Professor of Cardiology , Faculty of Medicine, Benha university, Egypt.
Cardiology Department, Faculty of Medicine, Benha university, Egypt.

References

1- Cao RY, Li Q, Miao Y, Zhang Y, Yuan W, Fan L. The Emerging Role of MicroRNA-155 in Cardiovascular Diseases. BioMed Research International. 2016; Article ID 9869208.
2- Getz GS, Vanderlaan PA and Reardon CA. The immune system and murine atherosclerosis. Curr Drug Targets. 2007; 8:1297–1306.
3- Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M and Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovascular Research. 2016; 111: 322–337.
4- da-Rocha ER. MicronRNA expression profiles in cardiovascular diseases. BioMed Research International. 2014; Article ID 985408, 23 pages.
5- Vishnoi A and Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. In: MicroRNA Profiling Methods and Protocols by Rani S; Springer Science+Business Media New York. 2017; 1-10.
6- Zhang YH, Xia LH, Jin JM, Zong M, Chen M and Zhang B. Expression level of miR-155 in peripheral blood. Asian Pac. J. Trop. Med. 2015; 8: 214-219.
7- Aghili N, Daher E and Carey Kimmelstiel C. Coronary angiography. In cardiology procedures, a clinical primer. By Hendel R. C. and Kimmelstiel C. Publisher: Springer; Chapter 28. 2016;237-248.
8- Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983; 51:606.
9- Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta CT) method. Methods. 2001; 25:402–408.
10- Schober A, Thum T and Zernecke A. MicroRNAs in vascular biology – metabolism and atherosclerosis. ThrombHaemost. 2012;107:603–604.
11- Chen LJ, Lim SH, Yeh YT, Lien SC and Chiu JJ. Roles of microRNAs in atherosclerosis and restenosis. Journal of Biomedical Science. 2012; 19:79.
12- Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010; 107: 677-684.
13- Zhu GF, Yang LX, Guo RW, Liu H, Shi YK, Ye JS., et al. microRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis. Jun. 2014; 25 (4):304-10.
14- D'Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P., et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One. 2013;8: e80345.
15- McCoy CE, Sheedy FJ, Qualls JE, Doyle SL, Quinn SR, Murray PJ., et al. IL-10 inhibits miR-155 induction by toll-like receptors. J Biol Chem. 2010; 285:20492–20498.
16- Huang RS, Hu GQ, Lin B, Lin ZY and Sun CC. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Invest Med. 2010; 58(8): 961-967.
17- Chen LJ, Lim SH, Yeh YT, Lien SC and Chiu JJ. Roles of microRNAs in atherosclerosis and restenosis. Journal of Biomedical Science; 2012; 19:79.
18- Andreou I, Sun X, Stone PH, Edelman ER and Feinberg MW. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307–318.
19- Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P., et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. BiochemBiophys Res Commun. 2010;394:792–797.
20- Wei Y, Schober A and Weber C. Pathogenic arterial remodeling: the good and bad of microRNAs. Am. J. Physiol. Heart Circ. Physiol. 2013; 304: 1050-1059.
21- Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 2012;122: 4190-4202.
22- Alan B, Akpolat V, Aktan A and Alan S. Relationship between osteopenic syndrome and severity of coronary artery disease detected with coronary angiography and Gensini score in men. ClinInterv Aging. 2016; 11:377-82.
23- Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X., et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011; 215:286–293.
24- Donners MM, Wolfs IM, Stöger LJ, van der Vorst EP, Pöttgens CC, Heymans S., et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One. 2012; 7:e35877.
25- Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X., et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 2012; 7:e46551.
26- Economou EK, Oikonomou E, Siasos G, Papageorgiou N, Tsalamandris S, Mourouzis K., et al. The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment. Atherosclerosis. 2015; 241: 624-633.
27- Wei Y, Zhu M, Corbalán-Campos J, Heyll K, Weber C and Schober A. Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis. Arterioscler. Thromb. Vasc. Biol.; 2015; 35: 796-803.
28- Schulte Z and Zeller T. microRNA-based diagnostics and therapy in cardiovascular disease-summing up the facts CardiovascDiagnTher. 2015; 5(1):17-36.
29- Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M and Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovascular Research.2016; 111: 322–337.
30- Laffont B and Rayner KJ. MicroRNAs in the pathobiology of atherosclerosis. Canadian Journal of Cardiology. 2017; 33: 1-170.
Published
2017-03-15
Issue
Vol 4 No 1 (2017)
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).